Moldvay Judit, Peták István
Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary.
Magy Onkol. 2012 Mar;56(1):38-49. Epub 2012 Jan 15.
Tailored therapy in lung cancer is one of the most exciting fields in translational research and also a nice example of fruitful collaboration between pulmonologists, clinical oncologists, pathologists and molecular biologists. This article, through a dialogue between a pathologist-clinician and a molecular biologist-pharmacologist, gives an overview about the most important questions on molecular targeted therapy in clinical practice, especially, EGFR-TKI treatment, EGFR activating mutations, as well as primary and acquired resistance.
肺癌的个体化治疗是转化研究中最令人兴奋的领域之一，也是肺科医生、临床肿瘤学家、病理学家和分子生物学家之间卓有成效合作的一个很好范例。本文通过一位病理学家兼临床医生与一位分子生物学家兼药理学家之间的对话，概述了临床实践中分子靶向治疗最重要的问题，特别是表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗、EGFR激活突变以及原发性和获得性耐药。
